MediLink Therapeutics
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
B3-101 Bio-Industrial Park Suzhou Indust...Phone Number
+86 51262858368Website
www.medilinkthera.comRevenue
$27.4 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About MediLink Therapeutics
Founded in 2020, MediLink Therapeutics is a biopharmaceutical company with a focus on conjugated drugs. The company has headquarters in Suzhou, China.Explore more
MediLink Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MediLink Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once MediLink Therapeutics has new funding data
Earning: See what the market has to say on MediLink Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when MediLink Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check if MediLink Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at MediLink Therapeutics
Click to see if MediLink Therapeutics had a recent Job posting/layoffs
MediLink Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if MediLink Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined MediLink Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
MediLink Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MediLink Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MediLink Therapeutics.
MediLink Therapeutics financials insights
Gather financial insights about MediLink Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$70M
MediLink Therapeutics Tech Stack
A closer look at the technologies used by MediLink Therapeutics
See more technologies
MediLink Therapeutics News & Media
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits
The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024. Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and expansion results. In extensive-stage SCLC patients, ORR was 68.1% and mPFS was 6.2 months. SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- MediLink Therapeutics (MediLink) today presented clinical data for YL201, a novel B7H3-targeting antibody drug conjugate (ADMediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology
SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors. Under the terms of the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and comMediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate
SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, on the development of a next-generation antibody-drug conjugate candidate ("ADC"), against Human Epidermal Growth Factor Receptor 3 (HER3). Under the terms of tNEXT Oncology and MediLink Therapeutics Take “Team Approach” to Next Level on Phase 1 First in Human Clinical Trial in San Antonio
SAN ANTONIO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for an antibody drug conjugate (ADC).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MediLink Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2020, MediLink Therapeutics is a biopharmaceutical company with a focus on conjugated drugs. The company has headquarters in Suzhou, China.... Read More
